Robotic Real-time Near Infrared Targeted Fluorescence Imaging in a Murine Model of Prostate Cancer: A Feasibility Study

Autor: Pedro F. Escobar, Warren D. W. Heston, Steve Huang, Cristina Magi-Galluzzi, Kelley M. Harsch, Sricharan Chalikonda, Georges-Pascal Haber, Robert J. Stein, Xinning Wang, Pravin K. Rao, Rakesh Khanna, Riccardo Autorino, Jihad H. Kaouk, Humberto Laydner, Wahib Isac, Bo Hu
Přispěvatelé: Laydner, H, Huang, S, Heston, Wd, Autorino, Riccardo, Wang, X, Harsch, Km, Magi Galluzzi, C, Isac, W, Khanna, R, Hu, B, Escobar, P, Chalikonda, S, Rao, Pk, Haber, Gp, Kaouk, Jh, Stein, Rj
Rok vydání: 2013
Předmět:
Zdroj: Urology. 81:451-457
ISSN: 0090-4295
Popis: Objective To evaluate the detection of near-infrared fluorescence from prostate tumors stained with a prostate-specific membrane antigen (PSMA)–targeted tracer developed in our institution with a novel robotic imaging system. Methods Prostate cancer cell lines PC3-pip (PSMA positive) and PC3-flu (PSMA negative) were implanted subcutaneously into 6 immunodeficient mice. When tumors reached 5 mm, a PSMA-targeted fluorescent conjugate was injected intravenously. The first 3 mice underwent near-infrared imaging immediately and hourly up to 4 hours after injection to determine the time necessary to obtain peak fluorescence and were killed. The last 3 mice were imaged once preoperatively and were euthanized 120 minutes later. Excision of the tumors was performed by using a novel robotic imaging system to detect near-infrared fluorescence in real time. Specimens were submitted for pathology. Results In the first 3 mice, we found 120 minutes as the time needed to observe peak fluorescence from the PSMA-positive tumors. We identified discrete near-infrared fluorescence from 2 of 3 PSMA-positive tumors with the robotic imaging system. Surgical margins were negative for all excised specimens except for one PSMA-negative tumor. Conclusions Real-time near-infrared fluorescence imaging of prostate cancer is feasible with a novel robotic imaging system. Further research is needed to optimize the signal intensity detectable from prostate cancer with our tracer. Toxicologic studies are needed before its clinical use.
Databáze: OpenAIRE